320 related articles for article (PubMed ID: 32157552)
1. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.
Marenco-Hillembrand L; Wijesekera O; Suarez-Meade P; Mampre D; Jackson C; Peterson J; Trifiletti D; Hammack J; Ortiz K; Lesser E; Spiegel M; Prevatt C; Hawayek M; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2020 Apr; 147(2):297-307. PubMed ID: 32157552
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
6. Survival Analysis of Glioblastoma Multiforme.
Witthayanuwat S; Pesee M; Supaadirek C; Supakalin N; Thamronganantasakul K; Krusun S
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2613-2617. PubMed ID: 30256068
[TBL] [Abstract][Full Text] [Related]
7. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
10. Survival improvements with adjuvant therapy in patients with glioblastoma.
Jayamanne D; Wheeler H; Cook R; Teo C; Brazier D; Schembri G; Kastelan M; Guo L; Back MF
ANZ J Surg; 2018 Mar; 88(3):196-201. PubMed ID: 28922698
[TBL] [Abstract][Full Text] [Related]
11. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
12. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
[TBL] [Abstract][Full Text] [Related]
13. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Rulseh AM; Vymazal J
J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
[TBL] [Abstract][Full Text] [Related]
14. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival?
Adeberg S; Bostel T; König L; Welzel T; Debus J; Combs SE
Radiat Oncol; 2014 Apr; 9():95. PubMed ID: 24758192
[TBL] [Abstract][Full Text] [Related]
15. Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients.
Zur I; Tzuk-Shina T; Guriel M; Eran A; Kaidar-Person O
Sci Rep; 2020 Jun; 10(1):9595. PubMed ID: 32533126
[TBL] [Abstract][Full Text] [Related]
16. Optimal adjuvant therapy in elderly glioblastoma: results from a systematic review and network meta-analysis.
Kalra B; Kannan S; Gupta T
J Neurooncol; 2020 Jan; 146(2):311-320. PubMed ID: 31894517
[TBL] [Abstract][Full Text] [Related]
17. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
19. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]